How Ozempic Affects Anxiety and Mental Health: What the Evidence Actually Shows

Ozempic was approved to treat type 2 diabetes. Wegovy was approved for weight management. Neither was designed as a psychiatric medication. But they both land in the brain, and what happens there is increasingly hard to ignore.

The GLP-1 receptor agonist class now affects tens of millions of people. The same mechanisms that suppress appetite also activate circuits involved in mood, reward, and stress response. That intersection has produced a genuinely complicated picture: some evidence pointing toward psychiatric benefit, some pointing toward risk, and a lot of people caught in the middle trying to figure out what it means for them.

This is what the current evidence actually shows.

What This Page Covers

• How GLP-1 receptors work in the brain and why they matter for mood
• What the gut-brain axis has to do with semaglutide’s psychiatric effects
• What large-scale RCT data shows about psychiatric safety
• What population-level cohort studies show, and why they conflict
• The FDA’s 2026 decision to remove the suicidality warning
• What this means for people with existing anxiety or depression who are taking GLP-1 medications
• What monitoring looks like in clinical practice

How GLP-1 Receptors Work in the Brain

GLP-1, glucagon-like peptide-1, is a hormone produced in the gut in response to food intake. It signals the pancreas to release insulin and tells the brain that you have eaten. That brain signal is the mechanism behind GLP-1 receptor agonists’ weight loss effect: appetite suppresses because the brain receives a sustained version of the post-meal satiety signal.

GLP-1 receptor agonist therapies were developed to mimic the peripheral effects of GLP-1, but it is now well established that their efficacy in treating obesity depends on reducing energy intake through their action in the central nervous system.

GLP-1 receptors are distributed throughout multiple brain regions: the hypothalamus, which regulates appetite and stress hormones; the amygdala, which processes fear and emotional memory; the nucleus tractus solitarius, which integrates gut signals with brain function; and the ventral tegmental area, part of the dopamine reward circuit.

This wide distribution is the reason semaglutide affects more than appetite. When you activate circuits that govern stress response, emotional memory, and reward, psychiatric effects, both positive and negative, are not a surprise. They are an expected consequence of where these drugs land.

The Gut-Brain Axis Connection

A separate pathway may also explain some of the psychiatric effects. Researchers recently demonstrated that liraglutide alleviates depression through a gut-brain pathway that operates independently of GLP-1 receptors. Using pharmacological and genetic approaches, the study found that liraglutide increased the abundance of Lactobacillus delbrueckii in the gut, which in turn restored levels of the endocannabinoid 2-arachidonoylglycerol. The elevation of this endocannabinoid mediated antidepressant effects by normalizing excessive neuronal activity in emotional processing brain regions.

This gut microbiome pathway may help explain why the results from clinical trials and population studies diverge. Individuals vary in their microbiome composition, which would produce variable antidepressant responses from the same medication. Someone whose gut microbiome responds to GLP-1s by increasing Lactobacillus delbrueckii may experience mood improvement. Someone whose does not, may not.

What the RCT Data Shows

For people without significant psychiatric history, the clinical trial evidence is reasonably reassuring.

A meta-analysis of 80 randomized clinical trials including 107,860 participants found no significant association between GLP-1 receptor agonist use and either serious psychiatric adverse events or nonserious psychiatric events compared to placebo. No significant change in depressive symptoms was observed across the trial populations studied.

A post-hoc analysis of the STEP 1, 2, 3, and 5 trials, the large semaglutide weight management trials, similarly reported a statistically significant but clinically negligible reduction in depressive symptoms among individuals without major psychiatric illness treated with semaglutide, and concluded that semaglutide did not increase the risk of depression or suicidal ideation in this population.

These results come with an important caveat: the original Wegovy and Zepbound clinical trials excluded individuals with a history of recent major depressive episodes or suicidal ideation. This gap leaves open the possibility of unintended psychiatric effects, not because the drugs are inherently harmful, but because their impacts haven’t been properly studied among users with mental health conditions. The people most likely to experience psychiatric side effects may be precisely those who were excluded from the pivotal trials.

The Conflicting Picture from Population Studies

Observational and pharmacovigilance studies tell a more complicated story. The disagreement across these data sources is real, not a methodological artifact.

Evidence of Benefit

A large Swedish national cohort study published in Lancet Psychiatry followed 95,490 people with diagnosed depression or anxiety. Among those who used semaglutide, the adjusted hazard ratio for worsening mental illness was 0.58 (95% CI: 0.51-0.65), meaning semaglutide use was associated with a 42% lower risk of psychiatric deterioration compared to non-use of GLP-1 receptor agonists. Liraglutide showed a similar but smaller protective association (aHR 0.82).

A meta-analysis combining RCTs and cohort studies reported a small but statistically significant reduction in depression scores with GLP-1 receptor agonist treatment, with more pronounced effects in patients with type 2 diabetes. Separately, a real-world cohort study found semaglutide was associated with lower risk of incident suicidal ideation (hazard ratio 0.27) compared to non-GLP-1 anti-obesity medications.

Evidence of Risk

A multinational pharmacovigilance study using VigiBase data through December 2024, across 2,061,901 adverse drug reaction reports, found significant disproportionality signals for anxiety (adjusted reporting odds ratio: 1.26, 95% CI: 1.18-1.35), depressed mood disorders (aROR: 1.70, 95% CI: 1.57-1.84), and suicidality (aROR: 1.45, 95% CI: 1.29-1.63) with semaglutide. The same study noted that these signals were more pronounced among patients already taking antidepressants or anti-anxiety medications.

A separate 2024 cohort study in Scientific Reports found a significantly elevated risk of psychiatric outcomes associated with GLP-1 receptor agonist use in patients with obesity, with higher rates of anxiety and suicidal outcomes observed, particularly in younger women.

Why the Studies Conflict

These contradictory findings are not an error. They reflect the genuine complexity of studying psychiatric effects in a population that already has high rates of depression, anxiety, and obesity-related metabolic distress.

Someone starting Ozempic for weight loss is statistically more likely to have pre-existing depression or anxiety than the general population. Confounding by indication, the tendency for sicker patients to receive more aggressive treatment, makes it genuinely hard to separate medication effects from the underlying condition. Pharmacovigilance databases capture reports without denominator populations, making signal magnitude hard to interpret in absolute terms.

“The data are mixed, and that mixed picture is the honest picture right now,” says Daniel Montville, MD, Psychiatrist, of the SiggyMD clinical team. “What I can say is that the randomized trial evidence is more reassuring than the observational data, and that neither should be dismissed. What the discrepancy tells me is that certain patients, those with pre-existing psychiatric illness, need closer monitoring when they start a GLP-1 medication.”

The FDA’s 2026 Decision

In 2026, the FDA requested removal of the suicidal behavior and ideation warning from GLP-1 receptor agonist medications, including Ozempic, Wegovy, Saxenda, and Zepbound, after an agency analysis found no causal connection between these medicines and suicidality. This followed the EMA’s 2024 conclusion that available evidence did not indicate a causal association between GLP-1 agonists and suicidal thoughts or actions.

The removal of a label warning is a meaningful regulatory conclusion. It reflects the totality of the evidence reviewed by the agency, including the large RCT meta-analyses and the prospective cohort data, and weighs them against the pharmacovigilance signals.

This does not mean the conversation about GLP-1s and mental health is over. It means the causal signal for suicidality was not strong enough to sustain a regulatory warning given the body of evidence. Monitoring for psychiatric symptoms in clinical practice remains appropriate, particularly for patients with existing mental health conditions.

The Role of Weight Loss Itself

One complication that the research literature frequently underweights: losing weight affects mood, sometimes in ways that are hard to attribute to the drug.

For many people, losing significant body weight improves mood and reduces depression. The relief from pain, improved sleep apnea, reduced physical limitations, and increased energy that accompany weight loss are all mood-relevant. A patient who reports feeling better mentally on semaglutide may be responding to the weight loss, not the drug’s direct neurological effects.

The reverse is also possible. For some patients, the appetite suppression effect of semaglutide produces a significant change in how food and pleasure are experienced. Food is a central source of comfort, reward, and social connection for many people. If those cues are sharply reduced, mood effects can follow, particularly in someone with an existing relationship between eating and emotional regulation.

Neither of these is a reason to avoid GLP-1s. Both are reasons to monitor mood as part of clinical follow-up when someone starts one.

What This Means for People with Anxiety or Depression

If you currently live with anxiety or depression and your prescriber is recommending a GLP-1 medication for type 2 diabetes or weight management, several things are worth knowing:

The clinical trials had limited enrollment of people with your history. The primary safety data for Wegovy were collected in populations that excluded active psychiatric conditions. Your risk profile may differ from what the trial averages show.

The large Lancet Psychiatry cohort suggests the association may be protective, not harmful, even in people with depression. But that is a population-level finding. Individual responses vary.

Psychiatric symptoms early in treatment or during dose escalations deserve attention. GLP-1 agonists may induce anxiety in some patients early in treatment; this has been observed in animal models and some clinical case reports, and it can subside with continued use. If you notice mood changes in the first several weeks, report them rather than wait for a scheduled appointment.

You should disclose your full mental health history to any prescriber before starting a GLP-1 medication, including current medications, history of depression, anxiety, bipolar disorder, and any prior episodes of suicidal ideation.

If your prescriber tracks your mood through regular check-ins, that monitoring can catch changes early. If they do not, ask how you should communicate mood changes between appointments.

If you are in crisis: call or text 988 (Suicide and Crisis Lifeline) or go to your nearest emergency room.

How SiggyMD Approaches Psychiatric Medication Monitoring

SiggyMD’s model is built around the recognition that psychiatric symptoms don’t hold to appointment schedules. Daily check-ins capture mood trajectory, sleep changes, anxiety levels, and side effect experience in real time. A licensed prescriber reviews this data continuously, not at quarterly intervals.

For patients on GLP-1 medications who are also managing anxiety or depression, that continuous visibility changes what’s possible. A mood drift that would go unnoticed for three months between appointments becomes visible within days.

“Patients on GLP-1s for metabolic reasons who also have a psychiatric history need someone watching their mood trajectory, not waiting for them to report a crisis,” says Daniel Montville, MD, Psychiatrist, of the SiggyMD clinical team. “The complexity here isn’t theoretical. These drugs are doing things in the brain. The clinical question is whether we are close enough to catch the signal before it becomes a problem.”

What Members Are Saying

KT

K.T., 41

Type 2 Diabetes and Generalized Anxiety

“My internist prescribed Ozempic without knowing my full psychiatric history. The first two weeks were rough, a lot more anxiety than usual. When I told my prescriber, we slowed the dose escalation and the anxiety settled. I’m glad I spoke up rather than stopping the medication entirely. My A1C came down significantly.”

RS

R.S., 52

Obesity and Major Depressive Disorder

“I was nervous to try a GLP-1 with my depression history. My psychiatrist coordinated with the prescribing doctor before I started. I’ve now been on it for seven months. If anything, the weight loss and the energy it brought back have helped my mood. But I was monitored closely the whole time.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

The Bottom Line

Ozempic and other GLP-1 receptor agonists affect the brain. That is not a safety concern by itself, it is a pharmacological fact. These drugs activate circuits involved in mood, reward, appetite, and stress. Some patients experience psychiatric benefit. Some experience psychiatric symptoms, particularly early in treatment or during dose increases.

The large RCT data do not show a meaningful psychiatric risk for most patients. The FDA’s 2026 label update removed the suicidality warning. The most rigorous population-level study in people with existing depression and anxiety showed a protective association.

But the gap in evidence remains real. The pivotal trials excluded patients with psychiatric history. Pharmacovigilance signals exist. Individual responses vary.

If you are taking or considering a GLP-1 medication and have a history of anxiety or depression, this conversation belongs in your clinical record, not as a reason to avoid the medication, but as context your prescribers need to monitor you appropriately.

Read more about how antidepressant medications work and what to expect during the first eight weeks, or start your anonymous intake with SiggyMD to connect with a licensed prescriber who can review your full clinical picture, including any GLP-1 medications you are taking and how they may interact with your mental health treatment.

Sources

1. FDA. FDA requests removal of suicidal behavior and ideation warning from GLP-1 receptor agonist medications. 2026.

2. Mittendorfer-Rutz E, et al. Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study. Lancet Psychiatry. 2026.

3. Sa J, et al. Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence. Diabetes, Obesity and Metabolism. 2026.

4. Guirguis A, et al. Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A VigiBase study. Journal of Affective Disorders. 2025.

5. Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine. 2024;30:168-176.

6. De Giorgi R, et al. An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders. Nature Mental Health. 2025.

7. Yao H, et al. Microbiota-driven gut-brain signaling underlies antidepressant effects of a GLP-1 analog. Cell Host & Microbe. 2026.

8. Manoharan S, et al. GLP-1 Agonists Can Affect Mood: A Case of Worsened Depression on Ozempic (Semaglutide). Cureus. 2024.

9. PMC. GLP-1 physiology and pharmacology along the gut-brain axis. 2025.

10. Think Global Health. The Mental Health Effects of Ozempic and GLP-1 Drugs. 2024.